TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
42 hedge funds and large institutions have $101M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 9 closing their positions.
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
11% more funds holding
Funds holding: 38 → 42 (+4)
2% more capital invested
Capital invested by funds: $99.3M → $101M (+$2.05M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
67% less call options, than puts
Call options by funds: $152K | Put options by funds: $464K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.68M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.44M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.36M |
| 4 |
Renaissance Technologies
New York
|
+$688K |
| 5 |
Two Sigma Investments
New York
|
+$627K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.52M |
| 2 |
Millennium Management
New York
|
-$937K |
| 3 |
6CM
683 Capital Management
New York
|
-$878K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$492K |
| 5 |
Goldman Sachs
New York
|
-$246K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Simplex Trading
Chicago,
Illinois
| – | -$1.16K | -6 | Closed |
|
TCON Hedge Fund Activity: Q1 2021 in Review
42 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2021, worth a combined $101M — up 2.1% from $99.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TCON positions and 9 closed out — a net gain of 4 holders — while 11 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.68M. The largest seller was Morgan Stanley, cutting an estimated $1.52M.
- 42 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2021, up from 38 in Q4 2020.
- Funds reported $101M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2021, up 2.1% quarter-over-quarter.
- 13 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 9 closed out, a net change of +4 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $3.68M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was Morgan Stanley, an estimated $1.52M sold.
Based on aggregated 13F filings for Q1 2021.